Fasting GLP-1 levels in women with PCOS and CAH
DOI:
https://doi.org/10.2478/AMB-2024-0071Keywords:
CAH, PCOS, GLP-1, hyperandrogenism, incretinAbstract
Background: Polycystic ovarian syndrome (PCOS) is the most prevalent condition associated with increased androgens, but some rare diseases, e.g., congenital adrenal hyperplasia (CAH), should also be considered in the differential diagnosis of hyperandrogenemia. The potential role of incretin hormones has been thoroughly studied in different metabolic conditions, but data about women with PCOS and CAH are insufficient. Aims: Therefore, the present study aims to investigate the fasting GLP-1 levels in women with PCOS and CAH compared to healthy women and to establish the possible associations with the ovarian and adrenal androgens, obesity, and hyperinsulinemia in these conditions. Methods: Fasting GLP-1 levels were measured in 47 women with PCOS, 11 CAH patients, and 26 healthy volunteers. The associations between the GLP-1, metabolic, and hormonal characteristics in the investigated groups have been studied. Results: GLP-1 levels did not differ between healthy women and patients with PCOS but were significantly higher in CAH patients (p = 0.025). CAH patients were similarly obese as PCOS women, but they showed increased testosterone (p = 0.009), 11-ketotestosterone (p = 0.046), 17-OH-progesterone (p < 0.001), and insulin levels (p = 0.043), and lower luteinizing hormone (p = 0.002) and dehydroepiandrosterone-sulfate levels (p = 0.004). In the PCOS group, the fasting GLP-1 levels were positively related to BMI (r =
+0.327; p = 0.024) but not to other hormonal or metabolic indices. Conclusions: Our results show increased fasting GLP-1 and insulin levels in CAH individuals compared with PCOS patients but similar fasting GLP-1 levels in PCOS and healthy women. Further studies are necessary to clarify the incretin effects and the role of incretin-based therapy in women with different hyperandrogenic states and increased metabolic risk.
References
Rasquin LI, Anastasopoulou C, Mayrin JV. Polycystic Ovarian Disease. 2022 Nov 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
Teede HJ, Misso ML, Costello MF, et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018, 110(3):364-379.
Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2018, 103(11):4043-4088.
Sam S. Obesity and Polycystic Ovary Syndrome. Obes Manag, 2007, 3(2):69-73.
Tsenkova P, Robeva R, Elenkova A, Zacharieva S. Prevalence and characteristics of the polycystic ovarian syndrome in overweight and obese premenopausal women. Acta Endocrinol (Buchar), 2022, 18(4):417-423.
Falhammar H, Frisén L, Hirschberg AL, et al. Increased Cardiovascular and Metabolic Morbidity in Patients With 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study. J Clin Endocrinol Metab, 2015, 100(9), 3520-3528.
Brandfon S, Eylon A, Khanna D, Parmar MS. Advances in Anti-obesity pharmacotherapy: current treatments, emerging therapies, and challenges. Cureus, 2023; 15(10):e46623.
Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metabol, 2004, 287:E199-E206.
Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Front Endocrinol (Lausanne), 2018, 9:672.
Lin T, Li S, Xu H, et al. Gastrointestinal hormone secretion in women with polycystic ovary syndrome: an observational study. Hum Reprod, 2015, 30(11):2639-2644.
Aydin K, Arusoglu G, Koksal G, et al. Fasting and post-prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndrome. Clin Endocrinol (Oxf), 2014, 81(4):588-592.
Robeva R, Elenkova A, Kirilov G, Zacharieva S. Plasma-free metanephrines, nerve growth factor, and renalase significance in patients with PCOS. Endocrine. 2023;81(3):602-612.
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care, 2004, 27(6):1487-1495.
Gama R, Norris F, Wright J, et al. The entero-insular axis in polycystic ovarian syndrome. Ann Clin Biochem, 1996, 33 (Pt3):190-195.
Vrbikova J, Hill M, Bendlova B, et al. Incretin levels in polycystic ovary syndrome. Eur J Endocrinol, 2008, 159(2):121-127.
Cassar S, Teede HJ, Harrison CL, et al. Biomarkers and insulin sensitivity in women with Polycystic Ovary Syndrome: Characteristics and predictive capacity. Clin Endocrinol (Oxf), 2015, 83(1):50-58.
Glintborg D, Mumm H, Holst JJ, Andersen M. Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome. Endocr Connect, 2017, 6(4):267-277.
Pontikis C, Yavropoulou MP, Toulis KA, et al. The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: a pilot study. J Womens Health (Larchmt), 2011, 20(6):971-976.
Ferjan S, Jensterle M, Oblak T et al. An impaired glucagon like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity. J Int Med Res, 2019, 47(10):4691-4700.
Svendsen PF, Nilas L, Madsbad S, Holst JJ. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism, 2009, 58(5):586-593.
Stinson SE, Jonsson AE, Lund MAV, et al. Fasting Plasma GLP-1 Is Associated with Overweight/Obesity and Cardiometabolic Risk Factors in Children and Adolescents. J Clin Endocrinol Metab, 2021, 106(6):1718-1727.
Vilsbøll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab, 2003, 88(6):2706-2713.
Chia CW, Carlson OD, Liu DD, et al. Incretin secretion in humans is under the influence of cannabinoid receptors. Am J Physiol Endocrinol Metab, 2017, 313(3):E359-E366.
Dybjer E, Engström G, Helmer C, et al. Incretin hormones, insulin, glucagon and advanced glycation end products in relation to cognitive function in older people with and without diabetes, a population-based study. Diabet Med, 2020, 37(7):1157-1166.
Kubota S, Yabe D. Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe? J Clin Endocrinol Metab, 2021, 106(9):e3778-e3780.
Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes, 2008, 57(5):1340-1348.
Ejarque M, Guerrero-Pérez F, de la Morena N, et al. Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes. Sci Rep, 2019, 9(1):6274.
Pugliese G, de Alteriis G, Muscogiuri G, et al. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? J Endocrinol Invest, 2023, 46(9):1761-1774.
Pall M, Azziz R, Beires J, Pignatelli D. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertil Steril, 2010, 94(2):684-689.
Auchus RJ, Arlt W. Approach to the patient: the adult with congenital adrenal hyperplasia. J Clin Endocrinol Metab, 2013, 98(7):2645-2655.
Nordenström A, Lajic S, Falhammar H. Long-Term Outcomes of Congenital Adrenal Hyperplasia. Endocrinol Metab (Seoul), 2022, 37(4):587-598.
Sato T, Hayashi H, Hiratsuka M, Hirasawa N. Glucocorticoids decrease the production of glucagon-like peptide-1 at the transcriptional level in intestinal L-cells. Mol Cell Endocrinol, 2015, 406:60-67.
Kappe C, Fransson L, Wolbert P, Ortsäter H. Glucocorticoids suppress GLP-1 secretion: possible contribution to their diabetogenic effects. Clin Sci (Lond), 2015, 129(5):405-414.
Lu Y, Wang E, Chen Y, et al. Obesity-induced excess of 17-hydroxyprogesterone promotes hyperglycemia through activation of glucocorticoid receptor. J Clin Invest, 2020, 130(7):3791-3804.
Turcu AF, Auchus RJ. Clinical significance of 11-oxygenated androgens. Curr Opin Endocrinol Diabetes Obes, 2017, 24(3):252-259.
Turcu AF, Nanba AT, Chomic R, et al. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in
classic 21-hydroxylase deficiency. Eur J Endocrinol, 2016, 174(5):601-609.
Yoshida T, Matsuzaki T, Miyado M, et al. 11-oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome. Endocr J, 2018, 65(10):979-990.
Auer MK, Hawley JM, Lottspeich C, et al. 11-Oxygenated androgens are not secreted by the human ovary: in-vivo data from four different cases of hyperandrogenism. Eur J Endocrinol, 2022, 187(6):K47-K53.
O’Reilly MW, Kempegowda P, Jenkinson C, et al. 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome. J Clin Endocrinol Metab, 2017, 102(3):840-848
Downloads
Published
Issue
Section
License
Copyright (c) 2024 R. Robeva, G. Kirilov, A. Elenkova, S. Zacharieva (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
